UroNova GmbH - Technology

UroNova is specialised in developing and producing molecular coatings for medical disposables and devices. Coatings that lead to a level of care that feels exceptional to the patient and the care provider.

UroNova Molecular Inhibitor Coating

The UroNova Molecular Inhibitor Coating is specifically designed to minimise infection, bioflim formation and encrustation. This enables significantly prolonged indwelling times, health economic benefits and a reduction of pain for the patients:

Infection & Encrustation ê
Indwelling Time é
Morbidity & Medication ê
Emergencies ê
Overall Costs ê
Patients Quality of Life é

Left: Raster electron microscopy of E. coli bacteria.
Right: Raster electron microscopy of encrustation crystals.

The UroNova Molecular Inhibitor Coating completely covers the inner and outer surface of the implant or catheter with macromolecular inhibitors. These substances are naturally contained in human urine, being effective against infection and stone formation. Due to its antimicrobial properties the coating proved to be clinically effective as well in other environments, like in bile.

The coating is built up completely with covalent bonds, the strongest bonds in chemistry. Therefore no drug elution takes place and no negative side effects or systemic reactions of the patient to an eluted drug can occur. Furthermore the effectiveness is timewise not limited by the size of the reservoir.

UroNova Molecular Inhibitor Coating structure:
Ultra thin and long-term stable by covalent bonding.

UroNova Cell Growth Coating

The UroNova Cell Growth coating enables a regular growth of vital cell groups and their proliferation on surfaces where normally no cell growth takes place.

Left: Medical suture with UroNova Cell Growth Coating
Right: Medical suture without coating.

So the UroNova Cell Growth Coating is accelerating healing processes and promoting rapid host tissue ingrowth of surgical and urological meshes. Due to its antimicrobial properties, it furthermore minimises the risk of chronic inflammation and infection.

The ultra thin coating is built up completely with covalent bonds, the strongest bonds in chemistry. Therefore no drug elution takes place and no negative side effects or systemic reactions of the patient to an eluted drug can occur. Furthermore the effectiveness is not limited by the size of the reservoir.

UroNova Haemocompatibility Coating

The UroNova Haemocompatibility Coating improves significantly the biocompatibility of implant surfaces in contact with blood.

Thrombus formation on an artificial heart valve.

By inactivating coagulation factor Xa the UroNova Haemocompatibility coating interrupts the coagulation cascade. As this is done in a catalytic process, no drug release is necessary. Therefore the ultra thin coating is built up completely with covalent bonds, the strongest bonds in chemistry. No negative side effects or systemic reactions of the patient to an eluted drug can occur. Furthermore the effectiveness is timewise not limited by the size of the reservoir.